$DFFN News

Last published 3y ago

3y agoDFFNDiffusion Pharmaceuticals Stockholders Approve Merger with EIP PharmaGlobeNewswireApproximately 71% of Stockholders Voted in Favor of the TransactionDiffusion Announces 1-for-1.5 Reverse Stock SplitMerger on Track to Close on August 16, 2023 CHARLOTTESVILLE, Va., Aug. 15, 2023 (GLOBE NEWSWIRE) --
3y agoBGRY DFFN KBAL KMFMoore Kuehn Encourages DFFN, KMF, CSTI, and BGRY Investors to Contact Law FirmPR NewswireNEW YORK, March 30, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
3y agoDFFNEIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative DiseasesGlobeNewswireCombined company will pursue late-stage clinical development of oral neflamapimod for the treatment of dementia with Lewy bodies EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21
3y agoDFFNDiffusion Pharmaceuticals Announces Agreement with LifeSci Special OpportunitiesGlobeNewswireLifeSci Special Opportunities Master Fund Announces Support for Diffusion's Ongoing, Board-led Strategic Review Process and for Diffusion's Nominees at 2022 Annual Meeting New Director to be Appointed to Diffusion
3y agoDFFN REVB SNCE VINCDiffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeSci's History of Stockholder Value Destruction and Self-DealingGlobeNewswireDiffusion has a highly engaged and independent board that possesses the right skills and experience to execute the strategic review processDiffusion received bids from more than 15 companies participating in review
3y agoDFFN POWWLifeSci Special Opportunities Responds to Recent Press Release Issued by Diffusion PharmaceuticalsGlobeNewswireSets the Record Straight on Diffusion's Misleading Narrative and Raises Concerns about a Troubling Pattern of Entrenchment and Lack of Accountability on the Board Has Nominated a Slate of Highly Qualified Directors
3y agoDFFNDiffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswireAnnounced Thorough Evaluation of a Range of Potential Strategic OpportunitiesContinued GBM Study Start-up ActivitiesEnded Quarter with $25.9 million in Cash, Cash Equivalents and Marketable Securities CHARLOTTESVILLE,
3y agoDFFNDiffusion Pharmaceuticals Sees Significant Progress in its Strategic Review ProcessGlobeNewswireDiffusion in Active Bidding Stage and Encouraged by Response to the Strategic Review Process Diffusion Board of Directors Rejects Woefully Inadequate, Unsolicited Offer for the Company by client of Investment Bank
4y agoDFFNDiffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSCGlobeNewswireCHARLOTTESVILLE, Va., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that may enhance the
4y agoDFFNDiffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswire• Aligned with FDA on Design of Phase 2 GBM Trial of TSC; Initiation Expected by End of 2022• Reported Positive Effects in TSC Altitude Trial• Ended Quarter with $28.5 million in Cash, Cash Equivalents and Marketable Securities• Expected
4y agoDFFNDiffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor OxygenationGlobeNewswireDiffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate ("TSC") in newly diagnosed glioblastoma multiforme ("GBM") patients Company to evaluate effects of TSC on tumor oxygena
4y agoDFFNDiffusion Pharmaceuticals Announces Positive Effects in Altitude TrialGlobeNewswirePositive effects on oxygenation observed with the 2.5 mg/kg dose at the end of the exercise interval Positive effects on post-exercise recovery based when comparing measurements 10 min post-exercise to measurements at the end of the exercise interval
4y agoDFFNDiffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory OfficerGlobeNewswireCHARLOTTESVILLE, Va., May 18, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing therapies that enhance the body's ability to deliver oxygen to areas where it is
4y agoDFFNDiffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment ConferenceGlobeNewswireCHARLOTTESVILLE, Va., May 17, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where
4y agoDFFNDiffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswireCompleted Dosing in Altitude Trial; Topline Data Expected in June 2022 Blinded, Interim Data to be Presented at UHMS Annual Scientific Meeting in May 2022 Ended Quarter with $32.6 Million in Cash, Cash Equivalents and Marketable Securities Regained C
4y agoDFFNDiffusion Pharmaceuticals Regains Compliance With Nasdaq Listing RequirementsGlobeNewswireCHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where
4y agoDFFNDiffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance PlanGlobeNewswireCHARLOTTESVILLE, Va., April 18, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas wher
4y agoDFFNDiffusion Pharmaceuticals Completes Dosing in Altitude TrialGlobeNewswireTopline data expected within two months Blinded, interim data to be presented at the Undersea & Hyperbaric Medical Society's Annual Scientific Meeting in May 2022 CHARLOTTESVILLE, Va., April 11, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals
4y agoDFFNDiffusion Pharmaceuticals Announces New Date for Previously Announced Special Meeting of StockholdersGlobeNewswire• Special Meeting of Stockholders Rescheduled to Monday, April 18, 2022 at 9:00 a.m. E.T.• No Change to Meeting Location, Record Date, or Proposals to Be Voted Upon CHARLOTTESVILLE, Va., April 08, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceutic
4y agoDFFNDiffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business UpdateGlobeNewswireAltitude Trial Dosing Expected To Be Completed in 2Q2022; mid-2022 for ILD-DLCO Trial Phase 2 Hypoxic Solid Tumor Study Protocol Submission Planned to Support 2H22 Study Start $37.3M in Cash & Cash Equivalents as of Year-End; Expected to Fund Operatio
4y agoDFFNDiffusion Pharmaceuticals Expands its Scientific Advisory Board with the Addition of Leading Radiation and Medical Oncology ExpertsGlobeNewswireCHARLOTTESVILLE, Va., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where
4y agoDFFNDiffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during "J.P. Morgan Week 2022"GlobeNewswireCHARLOTTESVILLE, Va., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where
4y agoDFFNDiffusion Pharmaceuticals Doses First Patients in ILD-DLCO TrialGlobeNewswireCHARLOTTESVILLE, Va., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where
4y agoDFFNDiffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523GlobeNewswireCHARLOTTESVILLE, Va., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where
4y agoDFFNDiffusion Pharmaceuticals Doses First Participants in Altitude TrialGlobeNewswireCHARLOTTESVILLE, Va., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where
5y agoDFFNDiffusion Pharmaceuticals Reports Third Quarter Financial Results and Provides Business UpdateGlobeNewswireAnnounces Intent to Develop TSC to Treat Hypoxic Tumors Altitude Trial Expected to Commence in November 2021 ILD-DLCO Trial Expected to Commence in Late December 2021 CHARLOTTESVILLE, Va., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharma
5y agoDFFNDiffusion Pharmaceuticals to Participate in the Alliance Global Partners Biotech & Specialty Pharma ConferenceGlobeNewswireCHARLOTTESVILLE, Va., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen t
5y agoDFFNDiffusion Pharmaceuticals Issues Letter to ShareholdersGlobeNewswireCHARLOTTESVILLE, Va., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen
5y agoDFFNRandomized, Double-Blind, Placebo-Controlled, Crossover Study of Trans Sodium Crocetinate in Healthy Volunteers Exercising at Altitude - NCT05036980ClinicalTrials.govSequence matched median PaO2 per dose cohort comparing TSC vs PBO, Sequence matched median VO2 per dose cohort comparing TSC vs PBO, Effect of TSC on Median Oxygen Saturation, Effect of TSC on Median Serum Lactate Concentration
5y agoDFFNDiffusion Pharmaceuticals to Present at the 23rd Annual H.C. Wainwright Global Investment ConferenceGlobeNewswireCHARLOTTESVILLE, Va., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen
5y agoDFFNDiffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDA's Pulmonology, Allergy, and Critical Care DivisionGlobeNewswirePhase 2 DLCO Trial in Interstitial Lung Disease Expected to Begin in Q4 Under New IND Fourth FDA Division to Clear TSC IND CHARLOTTESVILLE, Va., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (Diffusion
5y agoDFFNDiffusion Pharmaceuticals Reports Q2 Financial Results and Provides Business UpdateGlobeNewswireReports Improved Outcomes in Phase 1b COVID-19 Study and Positive Trend in Peripheral Oxygenation in Phase 1b TCOM Study Expects to Announce Initial Indication and Regulatory Pathway in Fourth Quarter of 2021 and Initiate Clinical Outcome Study in Fir
5y agoDFFNDiffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM TrialGlobeNewswireCHARLOTTESVILLE, Va., June 30, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen t
5y agoARHH AVCRF BABYF CLXPF+9Life Sciences Companies Investor Presentations Now Available for On-Demand ViewingGlobeNewswireNEW YORK, June 28, 2021 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced that the presentations from the June 24th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased
5y agoARHH AVCRF BABYF CLXPF+9Virtual Conference for Life Sciences Companies Broadcast Live June 24th, 2021GlobeNewswireNEW YORK, June 21, 2021 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will s
5y agoDFFNDiffusion Pharmaceuticals to Webcast Live at Life Sciences Investor ForumGlobeNewswireCHARLOTTESVILLE, Va., June 21, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen t
5y agoDFFNDiffusion Pharmaceuticals Reminds Stockholders to Vote Shares In Advance of Annual MeetingGlobeNewswireCHARLOTTESVILLE, Va., June 18, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion," "we" or the "Company"), an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver ox
5y agoDFFNDiffusion Pharmaceuticals Reports Final Results from Its Phase 1b Study of Trans Sodium Crocetinate in Hospitalized COVID-19 PatientsGlobeNewswireCHARLOTTESVILLE, Va., May 10, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to
5y agoDFFNDiffusion Pharmaceuticals Reports First Quarter Financial Results and Provides Business UpdateGlobeNewswireCHARLOTTESVILLE, Va., May 10, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to
5y agoDFFNDiffusion Pharmaceuticals Completes Enrollment and Dosing in TCOM StudyGlobeNewswireCHARLOTTESVILLE, Va., March 25, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
5y agoDFFNDiffusion Pharmaceuticals Doses First Participants in TCOM StudyGlobeNewswireCHARLOTTESVILLE, Va., March 18, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
5y agoDFFNDiffusion Pharmaceuticals Reports 2020 Financial Results and Provides Business UpdateGlobeNewswireCHARLOTTESVILLE, Va., March 17, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
5y agoDFFNDiffusion Pharmaceuticals, Inc. to Present at the H.C. Wainwright Global Life Sciences ConferenceGlobeNewswireCHARLOTTESVILLE, Va., March 04, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
5y agoDFFNDiffusion Pharmaceuticals Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares of Common StockGlobeNewswireCHARLOTTESVILLE, Va., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
5y agoDFFNDiffusion Pharmaceuticals Announces Closing of $30 Million Bought Deal Offering of Common StockGlobeNewswireCHARLOTTESVILLE, Va., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
5y agoDFFNDiffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 PatientsGlobeNewswireCHARLOTTESVILLE, Va., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel...
5y agoDFFNDiffusion Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $30 MillionGlobeNewswireCHARLOTTESVILLE, Va., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative clinical stage biopharmaceutical company...
5y agoDFFNDiffusion Pharmaceuticals Announces $10 Million Bought Deal Offering of Common StockGlobeNewswireCHARLOTTESVILLE, Va., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative clinical stage biopharmaceutical company...
5y agoDFFNDiffusion Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 ConferenceGlobeNewswireCHARLOTTESVILLE, Va., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced that the Company is participating in the...
6y agoDFFNDiffusion Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business UpdatesGlobeNewswireInitiated and Advanced Clinical Trial Evaluating Lead Product Candidate in COVID-19 Patients Announces Next Steps in Development Program for Lead Product Candidate Ended Quarter with $21.9...